2009

 

ICAAC

Disk Diffusion testing of CXA-101 and CXA-101 in Combination with Tazobactam against Target Pathogens (F1-1998)

Activity Profile of CXA-101 and CXA-101/tazobactam against Target Gram-positive and Gram-negative Pathogens (F1-1986)

Resistance Trends among Gram-positive Cocci across the US and the Activity Profile of Tigecycline against Resistant Isolates (C2-1957)

Activity Profile of Tigecycline (TIG) against Resistant (R ) Gram-negative (GN) Enterobacteriaceae (EN) in the US (C2-1956)

Carbapenem and Other Antipseudomonal Agents: In Vitro Activity among Lower Respiratory Tract and ICU Isolates of P. aeruginosa: 2006-2008 TRUST Data (C2-629)

In vitro Activity of Radezolid against MRSA Causing Skin and Wound Infections from the United States, Europe, and Asia (E-810)

In vitro Activity of TR-700 (Torezolid) and Linezolid against Gram-positive Clinical Isolates from a Phase 2 Complicated Skin Clinical Trial (C1-1364a)

Activity of Ceftazidime/NXL104 and Select Comparators against Geographically Diverse Clinical Isolates of Pseudomonas aeruginosa (E-194)

ICC Satellite Symposium

Antimicrobial susceptibility trends among respiratory pathogens: What are global surveillance initiatives telling us?

ECCMID

Activity profile of empiric respiratory tract infection agents against Streptococcus pneumoniae in Europe based on patient population (P1634)

Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008 (P1620)

A current look at the in vitro activity of oritavancin and vancomycin against isolates of S. aureus from both Europe and the US (P1637)

Activity of tigecycline against Acinetobacter spp. from various specimen sources collected in Europe over the past five years (P1590)

Profile of tigecycline and comparator agents against Gram-positive organisms collected across the United States and Europe in 2007-2008 (P1613)

Profile of tigecycline and other agents against enteric bacilli collected across Europe (P1607)

IDSA

Regional Prevalence of Methicillin-Resistant S. aureus (MRSA) and Analysis of Ceftobiprole Activity against MRSA from 2006-2008─Results from TRUST and TSN Surveillance

Activity Profile of Tigecycline against Prevalent Multi-drug Resistant Populations of Acinetobacter spp. in the United States

ISAAR

Tigecycline Activity against Gram-Positive and Gram-Negative Target Pathogens from Asia in 2007, including Isolates with Multidrug Resistance (SR 35)

SHEA

Longitudinal Analysis of the Susceptibility of E. coli to Empiric Urinary Tract Infection (UTI) Agents; Impact of the Introduction of Generic Ciprofloxacin on Fluoroquinolone Resistance (476)

ASM

Activity Profile of Carbapenems Against Gram-Negative Pathogens; Impact of Using Pharmacodynamic (PD) Breakpoints vs. Current Interpretive Criteria (A020)

Current Resistance Across the US Among Enterobacteriaceae and P. aeruginosa; Regional Antibiogram of Doripenem and Comparators (A088)

Resistance Mechanisms in Ciprofloxacin-Resistant Escherichia coli Compared to Levofloxacin (A055)

2008

ICAAC/IDSA

Activity Profile of CXA-101against Gram-Positive and Gram-Negative Pathogens by Broth and AgarDilution

Mode of Action of CXA-101 Basedon Minimum Bactericidal Concentration (MBC) Analysis and Timekill Kinetic(TK) Analysis

Effect of Various TestingParameters on the Activity of CXA-101 by Broth Microdilution

Levofloxacin Susceptibility of S.pneumoniae (SP) and H. influenzae (HI) from Various Age GroupsAcross Asia: Results from GLOBALSurveillance Program

Activity of NZ2114 against Staphylococcaland Streptococcal Isolates, Including Resistant Phenotypes

Minimum BactericidalConcentration (MBC) Analysis and Timekill Kinetic (TK) Analysis of NZ2114against Staphylococci and Streptococci

Common Sources of S. aureus Infectionin the US and Prevalence of MRSA; Longitudinal Analysis of CeftobiproleActivity Against S. aureus from Prevalent Specimen Sources

Doripenem activity againstrecent Enterobacteriaceae from the US and resistant entericpopulations, including those with putative carbapenemases

In vitro Activity ofOritavancin against Gram-positive Organisms in Europe: A Comparative Study of Clinical Trialand Surveillance Results

Tigecycline Activity Profileagainst Acinetobacter baumannii: Comparative Study of a Recent CentralizedBroth Microdilution Surveillance Initiative and Results from LocalLaboratory Testing by E-test

Comparison of the TigecyclineEnterobacteriaceae Activity Profiles in the US Generated from CentralizedSurveillance by Broth Microdilution and from Localized Testing by VITEK2

Current In Vitro Activity ofTigecycline against Streptococcus pneumoniae and Haemophilus influenzaeIsolates from the UnitedStates

ECCMID

Anti-enterococcaland anti-sreptococcal activity profile of oritavancin in Europe

Invitro activity profile of oritavancin against resistant staphylococcalpopulations from a recent surveillance initiative in Europe

Tigecyclineactivity against Staphylococcus aureus exhibiting multidrug-resistantphenotypes in Europe

Analysisof tigecycline activity against Staphylococcus aureus based on patient locationand clinical specimen source in Europe

Susceptibilityof Staphylococcus aureus among skin and wound specimen sources in the United States:laboratory-based surveillance study 2005-2007

Alongitudinal perspective on Streptococcous pneumoniae, Haemophilus influenzae,and Moraxella catarrhalis resistance trends in Europe:from GLOBAL surveillance studies

Invitro activity of ceftobiprole against select Gram-positive and Gram-negative pathogensisolated from Europe in 2006-2007

Analysisof tigecycline activity against Enterobacteriaceae and Acinetobacter spp. basedon patient location and clinical specimen source in Europe

Tigecyclineactivity against geographically diverse Acinetobacter spp. displayingmulti-drug resistant phenotypes across Europe

Invitro activity of doripenem relative to meropenem and imipenem againstEnterobacteriaceae and P. aeruginosa isolates from Europe(2006-2007)

Tigecyclineactivity against geographically diverse Enterobacteriaceae displaying multidrug-resistant phenotypes across Europe

Currentsusceptibility patterns for H. influenzae and M. catarrhalis isolates from Europe: findings of the 2007 GLOBAL surveillance program

Epidemiologyof elevated fluoroquinolone MICs of S. pneumoniae, H. influenzae, and M.catarrhalis from the GLOBAL Study (1999-2005)

 

2007

ICAAC

Analysis of Doripenem Activity, Relative to Other Carbapenems, Against Target Gram-Negative Pathogens Isolated From Specific Infection Sites

A Longitudinal Perspective of Tigecycline Activity in the US against Staphylococcus aureus, Acinetobacter spp., and Enterobacteriaceae Exhibiting Multi-drug Resistant (MDR) Phenotypes

A Profile of Ceftobiprole (BPR) Activity Against Recent US Isolates of Enterobacteriaceae (EN) and Pseudomonas aeruginosa (PA) From Inpatients and ICU Patients

In Vitro activity of iclaprim against clinical isolates of Legionella pneumophila

Baseline Surveillance Profile of Cethromycin Activity against Streptococcus pneumoniae (SP); Results of the US Surveillance Initiative

Stratified Analysis of Doripenem Activity Against Enterobacteriaceae and Pseudomonas aeruginosa According to Patient Location: Inpatients and ICU Patients

7. Comparative Activities of Tigecycline among Recent Surveillance Isolates Tested by E-test and Broth Microdilution

5-Year Surveillance (2003-2007) of Anti-pneumococcal Activity of Oral Agents Recommended for the Empirical Treatment of Community Aquired Pneumonia (CAP) in Adults

Anti-Streptococcal Activity Profile of Oritavancin, a Potent Lipoglycopeptide under Development for Use against Gram-Positive Infections

In Vitro Activity Profile of Oritavancin against Resistant Staphylococcal Populations from a Recent Surveillance Initiative

In Vitro Activity Profile of Ceftobiprole (BPR), a Broad-Spectrum Anti-MRSA Cephalosporin, Against Recent S. aureus (SA) Isolated From Specific Clinical Specimens

In Vitro Activity of Cethromycin against a Recent and Diverse Collection of Haemophilus influenzae Isolates

Newly Defined in Vitro Quality Control Ranges for Oritavancin Broth Microdilution Testing and the Effect of Variations in Testing Conditions on MIC Results

Anti-Enterococcal Activity Profile of Oritavancin, a Potent Lipoglycopeptide under Development for Use against Gram-Positive Infections

In Vitro Activity Profile of Oritavancin against a Broad Spectrum of Aerobic and Anaerobic Bacterial Pathogens

Bactericidal activity and post antibiotic effect of iclaprim (ICL) against Staphylococcus aureus (SA)

Iclaprim (ICL): Defined quality control (QC) limits for MIC and disk diffusion (DD) susceptibility testing according to CLSI M23-A2 procedures

In Vitro Activity Profile of Oritavancin (ORI) against Organisms Demonstrating Key Resistance Profiles to Other Antimicrobial Agents

IDSA

Analysis of Levofloxacin and Comparator Antibiograms against Urinary Tract Infection (UTI) Isolates of E. coli and Other Enterobacteriaceae Across the United States

Surveillance Profiling of Doripenem Activity Against Pseudomonas aeruginosa Isolated From Inpatients and ICU Patients: Results of the TRUST Surveillance Initiatives

Ceftobiprole (BPR) Activity Against MRSA Stratified According to Patient Population and Specimen Source: Results of the Recent TRUST Surveillance Initiative

ECCMID

Europe Surveillance Initiative Profiling the Activity of Telavancin Against Streptococci by Specimen Source From 2004 to 2005

Baseline Surveillance Profile of Doripenem Against Key Gram-Negative Pathogens Encountered in Europe

Profile of Ceftobiprole Activity Against S. aureus, S. pneumoniae, Enterobacteriaceae, P. aeruginosa and Acinetobacter spp.: Results of the 2005-2006 Surveillance Program

Europe Surveillance Initiative Profiling the Anti-staphylococcal Activity of Telavancin by Specimen Source from 2004 to 2005

Europe Surveillance Initiative Profiling the Anti-enterococcal Activity of Telavancin by Specimen Source from 2004 to 2005

Analysis of Tigecycline Activity against Acinetobacter spp. and Enterobacteriaceae Based on Clinical Specimen Source

Current Susceptibility Patterns for Streptococcus pneumoniae and Haemophilus influenzae Isolates from Europe: Findings of the 2005-2006 GLOBAL Surveillance Program

Evalutation of Isavuconazole E-test Compared to Broth Microdilution Antifungal Susceptibility Testing against Quality Control Strains and Clinical Candida Isolates

Baseline Profile of RO4908463 (CS-023) against Recent Isolates of Target Gram-Negative Pathogens Exhibiting ß-Lactam Resistant Phenotypes from Europe (EU), 2003-2006

Comparison of Baseline Profiles of RO4908463 (CS-023) against Recent Isolates of Target Gram-Possitive Pathogens Exhibiting Key Resistance Phenotypes Obtained from Europe and the USA 2003-2006

2006

ICAAC

Increasing Prevalence of High Level Macrolide Resistance among Streptococcus pneumoniae in the United States

Comparative In Vitro Potency of Oritavancin, Teicoplanin, and Vancomycin against Glycopeptide-Susceptible and -Resistant Gram-Positive Organisms

Baseline Profile of Telavancin Activity against Streptococci: Results of the 2004-2005 US Surveillance Initiative

Interaction of Telavancin and Other Antrimicrobial Agents Tested against Key Gram-positive Species

In Vitro of Telavancin against Enterococci: Results of the 2004-2005 US Surveillance Initiative

Baseline Antistaphylococcal Profile of Telavancin: Results of the 2004-2005 US Surveillance Initiative

In Vitro Activity of API-1252, a Novel Antimicrobial Agent, against Select Methicillin-Resistant Staphylococcus aureus (MRSA) Strains Exhibiting Key Resistance Phenotypes

Activity of ME1036, a Novel Anti-MRSA Carbapenem, against Gram-Positive and Gram-Negative Pathogens

Baseline Profile of RO4908463 (CS-023) Against Recent Isolates of Target Gram-Positive Pathogens Exhibiting Key Resistance Phenotypes

Profile of Ceftobiprole (BPR) Activity Against Staphylococci and S. pneumoniae (SP): Results fo the 2005-2006 Surveillance Program

Baseline Surveillance Profiles of Ceftobiprole (BPR) Activity Against Enterobacteriaceae and P. aeruginosa (PA)

Discordant Levofloxacin (LV) and Ciprofloxacin (CP) Susceptibility Profiles among Common Gram-Negative Bacilli; Indication of Potential Differences in Mode of Action?

Telavancin Demonstrates a Low Potential for In Vitro Selection of Resistance among Key Target Gram-positive Species

Bactericidal Activity of RO4908463 (CS-023) Against Beta-Lactam-Susceptible and -Resistant Target Species

Baseline Profile of RO4908463 (CS-023) Against Recent Isolates of Target Gram-Negative Pathogens Exhibiting Beta-Lactam Resistance Phenotypes

RO4908463 (CS-023) Demonstrates a Low Potential for in vitro Selection of Resistance in S. aureus, S. pneumoniae, E. coli, E. cloacae, K. pneumoniae and P. aeruginosa

Surveillance of Tigecycline (TIG) Activty; Discordance between Natioinal Profiles Associated with Testing Protocol and Methods

Longitudinal Analysis of Tigecycline (TIG) Activity against Geographically Diverse Staphylococcus aureus (SA), Acinetobacter spp (AB), and Enterobacteriaceae (EN) Exhibiting Multi-drug Resistant (MDR) Penotypes

IDSA

Profiles of Tigecycline Activity Based on Patient Location and Clinical Specimen Source of Target Organisms

Baseline Surveillance of Telavancin In Vitro Activity against Staphylococci in Europe and Israel

Baseline Surveillance of Telavancin Activity against Enterococci in Europe and Israel

Antistreptococcal Profile of Telavancin Based of the 2004-2005 Surveillance Initiative in Europe and Israel

Fluoroquinolone Susceptibility Profiles of Recent Urinary Tract Isolates Obtained from Pediatric Patients

Increasing Prevalence of Multidrug Resistance Phenotypes among Staphylococcus aureus Encountered in the Outpatient Settings; Comparative Findings of the LEADER 2004 and 2005 Surveillance Programs

Longitudinal Analysis of Linezolid (LIN) Activity against Gram-positive Pathogens:  Comparison of Results for the LEADER 2004 and 2005 US Surveillance Programs

Comparative Susceptibility Patterns of Levofloxacin and Other Agents against Pediatric Respiratory Tract Isolates of Streptococcus pneumoniae (SP)

ECCMID

A Current Perspective on Streptococcus pneumoniae and Haemophilus influenzae Resistance Trends in Europe: GLOBAL Surveillance Study 2005

Comparative Analysis of Levofloxacin and Ciprofloxacin Activity against Gram-Negative Pathogens Collected in Five European Countries Grouped by Site of Infection from GLOBAL Surveillance - 2005

Benchmarking Tigecycline Activity against Gram-positive and Gram-negative Pathogens with Multi-drug Resistance Phenotypes derived from Patient Specimens from the USA and Europe

2005

ICAAC

Screening of Levofloxacin-Susceptible Streptococcus pneumoniae Isolates from Clinical Trial Patients with Pneumonia for Mutations in parC or parE: Clinical and Microbiological Outcomes

Baseline Tigecycline (TIG) Activity Against Current and Geographically Diverse Staphylococcus aureus (SA) Strains Exhibiting Key Resistance Phenotypes

Comparison of Antimicrobial Resistance Profiles between Inpatient and Outpatient Escherichia coli Populations

Telavancin Activity Against Current and Diverse Staphylococcus aureus Populations

Telavancin Activity Against Current and Diverse Populations of Enterococci and Streptococcus pneumoniae

In vitro Activity of Linezolid Against Key Gram-Positive Organisms Isolated in the United States: Results of the LEADER 2004 Surveillance Program

Comparative Analysis of Antimicrobial Phenotypes between Streptococcus pneumoniae Populations Isolated from the Community and Hospital Settings

In Vitro Potency and Spectrum of Novel Rifamycins ABI-0043, ABI-0094, and ABI-0299

In Vitro Activity of Retapamulin and Comparators against 1690 Recent Gram-Positive Clinical Isolates

Dalbavancin Demonstrates a Low In Vitro Potential for Selection of Resistance in Staphylococci

IDSA

Antimicrobial Resistance Trends Among Sinus Isolates of Streptococcus pneumoniae from the United States: 2000-2005

Role of Efflux and QRDR Mutations among Streptococcus pneumoniae Isolates with Reduced Susceptibilities to Ciprofloxacin

Baseline Tigecycline (TIG) Activity Against a Diverse and Current Collection of Enterobacteriaceae (EB) and Acinetobacter (AC) Exhibiting Multi-drug Resistnace

Current Antimicrobial Resistance Profiles Among Methicillin-Resistant Staphylococcus aureus Encountered in the Outpatient Setting: Analysis of LEADER 2004 Surveillance Program Results

Ceftobiprole (BAL9141), an Investigational Cephalosporin With Activity Against MRSA, Demonstrates In Vitro Activity Against Clinical Isolates of Pseudomonas aeruginosa

ECCMID

A Baseline Assesment of the Activity of Telavancin against a Collection of Gram-Positive Isolates, including Resistant Phenotypes

Activity and Pharmacodynamics of RO4908463 (CS-023), a Unique Guanidine-Pyrrolidine Carbapenem with Activity against MRSA

Investigation of Divergent Piperacillin and Piperacillin/tazobactam Activities to Support Appropriate Formulary Decisions

The Prevalence of Multidrug Resistance Among Streptococcus pneumoniae (SP) in the USA

Activity of Ceftobiprole against Recent Clinical Isolates of Enterobacteriaceae from Respiratory Infections from Hospitalized Patients in Europe and USA